论文部分内容阅读
目的探讨诺和锐特充治疗妊娠糖尿病的临床效果及安全性。方法将75例妊娠糖尿病患者按不同治疗方案随机分为对照组和观察组,观察组39例,对照组36例。两组患者均进行饮食、运动干预,观察组给予诺和锐特充控制血糖,对照组用诺和灵R,治疗4周,对两组患者血糖控制情况及母婴围生期结局进行综合比较。结果观察组患者在治疗后的血糖水平较对照组更低,差异有统计学意义(P<0.05);观察组出现新生儿低血糖、妊娠高血压综合征(妊高症)、羊水过多发生率明显低于对照组,差异有统计学意义(P<0.05)。结论诺和锐特充治疗妊娠糖尿病效果突出,对于控制孕产妇血糖及改善围生期母婴结局效果显著,值得临床推广应用。
Objective To investigate the clinical effect and safety of Novo-Rui special treatment for gestational diabetes mellitus. Methods Seventy-five patients with gestational diabetes mellitus were randomly divided into control group and observation group according to different treatment plans, 39 cases in observation group and 36 cases in control group. The two groups of patients were diet, exercise intervention, the observation group was given Novo Rui special blood glucose control, the control group with Novolin R treatment for 4 weeks, the two groups of patients with glycemic control and maternal and neonatal outcomes for a comprehensive comparison . Results The blood sugar level of the observation group was lower than that of the control group (P <0.05). The incidence of neonatal hypoglycemia, pregnancy-induced hypertension (PIH) and polyhydramnios The rate was significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion Nuo-Rui special treatment of gestational diabetes mellitus outstanding results for the control of maternal blood sugar and improve the outcome of perinatal maternal and infant results are significant, worthy of clinical application.